Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation.

NeuroImage
Christopher G SchwarzClifford R Jack

Abstract

Since tau PET tracers were introduced, investigators have quantified them using a wide variety of automated methods. As longitudinal cohort studies acquire second and third time points of serial within-person tau PET data, determining the best pipeline to measure change has become crucial. We compared a total of 415 different quantification methods (each a combination of multiple options) according to their effects on a) differences in annual SUVR change between clinical groups, and b) longitudinal measurement repeatability as measured by the error term from a linear mixed-effects model. Our comparisons used MRI and Flortaucipir scans of 97 Mayo Clinic study participants who clinically either: a) were cognitively unimpaired, or b) had cognitive impairments that were consistent with Alzheimer's disease pathology. Tested methods included cross-sectional and longitudinal variants of two overarching pipelines (FreeSurfer 6.0, and an in-house pipeline based on SPM12), three choices of target region (entorhinal, inferior temporal, and a temporal lobe meta-ROI), five types of partial volume correction (PVC) (none, two-compartment, three-compartment, geometric transfer matrix (GTM), and a tau-specific GTM variant), seven choices of ref...Continue Reading

References

Jul 1, 1992·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·H W Müller-GärtnerJ J Frost
Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
Jul 1, 1990·Journal of Computer Assisted Tomography·C C MeltzerJ J Frost
Mar 11, 1999·Annals of Neurology·J L Price, J C Morris
Jun 16, 2005·NeuroImage·John Ashburner, Karl J Friston
Oct 13, 2009·NeuroImage·Brian B AvantsJames C Gee
Jan 18, 2012·NeuroImage·Bruce Fischl
Mar 21, 2012·NeuroImage·Martin ReuterBruce Fischl
Oct 29, 2014·Acta Neuropathologica·John F CraryPeter T Nelson
Mar 7, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Kewei ChenUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Mar 7, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Susan M LandauWilliam J Jagust
Mar 24, 2015·NeuroImage·Prashanthi VemuriUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Oct 28, 2015·Annals of Neurology·Keith A JohnsonReisa Sperling
Mar 5, 2016·Neuron·Michael SchöllWilliam J Jagust
Jun 15, 2016·Acta Neuropathologica Communications·Val J LoweMelissa E Murray
Oct 27, 2016·Physics in Medicine and Biology·Benjamin A ThomasKjell Erlandsson
Dec 21, 2016·Annals of Neurology·Marta MarquiéTeresa Gómez-Isla
Apr 4, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Adam S FleisherMark A Mintun
Jun 8, 2017·NeuroImage·Anne MaassUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Aug 5, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Jae Yong ChoiChul Hyoung Lyoo
Aug 23, 2017·Seminars in Nuclear Medicine·Chester A MathisWilliam E Klunk
Oct 20, 2017·Acta Neuropathologica Communications·Marta MarquiéTeresa Gómez-Isla
Nov 11, 2017·Data in Brief·Suzanne L BakerWilliam J Jagust
Dec 2, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Sudeepti SouthekalMark A Mintun
Dec 2, 2017·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Anne MaassWilliam J Jagust
Dec 12, 2017·Brain : a Journal of Neurology·Val J LoweClifford R Jack
Dec 30, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Michael D DevousMark A Mintun
Mar 15, 2018·Brain : a Journal of Neurology·Clifford R JackRonald C Petersen
Apr 5, 2018·Journal of Alzheimer's Disease : JAD·Katerina A TetzloffJennifer L Whitwell
Apr 5, 2018·Journal of Alzheimer's Disease : JAD·Christopher M LeeKeith A Johnson
May 22, 2018·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Adam J SchwarzUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jun 16, 2018·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Johan LiljaAgneta Nordberg
Aug 3, 2018·Neurology·Andrew J AschenbrennerJason J Hassenstab
Oct 8, 2018·Neurobiology of Aging·Stephanie A SchultzTammie L S Benzinger
Oct 17, 2018·JAMA : the Journal of the American Medical Association·Rik OssenkoppeleOskar Hansson
Nov 27, 2018·Journal of Alzheimer's Disease : JAD·Christopher G SchwarzClifford R Jack
Jan 1, 2019·Annals of Neurology·Theresa M HarrisonWilliam J Jagust
Mar 17, 2019·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Suzanne L BakerWilliam J Jagust

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.